A global study of asthma patients conducted by Rutgers and an international team of researchers found that the combination of the two drugs dramatically reduces the likelihood of an asthma attack.
The results of a clinical trial called MANDALA, published in New England Medical Journalshow that a combination of albuterol that provides relief from en asthma attack by relaxing smooth muscles and is used to immediately relieve asthma, while the corticosteroid budesonide, taken through an inhaler, reduces the number of sudden episodes of shortness of breath, wheezing and coughing in patients. Such incidents, which are medically referred to as “exacerbations” but are commonly known as asthma attacks, can often lead to first aid, hospitalization or, in some cases, death.
“This is a paradigm shift in the treatment of asthma. We consider this combination treatment, which is the first of its kind, as part of standard therapy, ”said author Reynold Panettiere Jr., Rutgers School of Medicine professor Robert Wood Johnson and vice chancellor for clinical and translational science.
Phase 3 clinical trial, which included more than 3,000 asthma patients from 295 locations across the United States, Europe, and South America, was developed to evaluate the safety and efficacy of a combination of albuterol and budesanide, both AstraZeneca PLC drugs, as a treatment for patients with moderate severe asthma. Albuterol is a short-acting beta-2 agonist that works by attaching to small proteins called beta-receptors in the airways, relaxing the muscles there. As a corticosteroid budesonide reduces swelling and irritation in the respiratory tract.
Standard “supportive” treatments include an inhaler that combines two drugs, one a long-acting beta-2 agonist such as benrolizumab and the other corticosteroids such as beclomethasone. When patients suffer from an asthma attack, they usually use life-saving medications such as albuterol. They are also often prescribed doses of oral steroids. Doctors are less likely to prescribe oral steroids because of their strong side effects.
The court was divided into three groups. With many patients already undergoing daily maintenance asthma therapy, group members were provided with one of three different therapeutic therapies in the event of asthma attacks. . The control group was given only albuterol.
The study concluded that patients not only improved lung function; they suffered fewer attacks.
The researchers found that albucid with a higher dose of budesanide reduces the risk of asthma attacks by 27 percent in the short term and reduces asthma attacks by 24 percent annually. This combination also reduced the use of corticosteroids, which can have adverse side effects, by 33 percent.
“With this new inhaler, which provides more inhaled steroids every time patients take rescue therapy, they get more at a time when they have an outbreak and when they need it,” said Panettiere, who is also with. is the director of the Rutgers Institute of Translational Medicine and Science and conducts research at the New Jersey Institute of Child Health. “We have shown that in addition to reducing their exacerbations, it has reduced their need for oral steroids after the outbreak.”
According to the Asthma and Allergy Foundation, there are about 25 million adults and children in the United States asthma.
Alberta Papi et al., Combined inhaler for the treatment of asthma with a fixed dose of albuterol and budesonide, New England Medical Journal (2022). DOI: 10.1056 / NEJMoa2203163
Citation: A combination of drugs reduces the risk of asthma attacks (2022, May 16) received May 16, 2022 from https://medicalxpress.com/news/2022-05-drug-combination-asthma.html
This document is subject to copyright. Except for any honest transaction for the purpose of private study or research, no part may be reproduced without written permission. The content is provided for informational purposes only.